Search bioRxiv⌕ Search

Biology subjects

Nakatani, T.

Publications and source records attributed to Nakatani, T..

2 recordsLinked to original sources

Concomitant DNA hydroxymethylation and histone H2B O-GlcNAcylation are prerequisites for zygotic genome activation in mice

The paternal chromatin undergoes extensive reprogramming, characterized by the loss of 5-methylcytosine (5mC) through Ten-eleven translocation 3 (Tet3)-mediated oxidation to 5-hydroxymethylcytosine (5hmC). Given the role of DNA methylation in gene silencing, it has long been posited that this loss of paternal DNA methylation facilitates zygotic genome activation (ZGA), which occurs predominantly on the paternal genome. However, recent evidence indicates that Tet3-mediated 5mC oxidation alone does not influence global transcription in zygotes, leaving the molecular mechanisms governing ZGA largely elusive. Here, we identify the functional significance of O-linked N-acetylglucosamine (O-GlcNAc) modification of histone H2B at Serine 112 (H2BS112GlcNAc), catalyzed by O-GlcNAc transferase (OGT), within the paternal chromatin of mouse zygotes. We demonstrate that OGT is selectively recruited to the paternal chromatin because Stella (also known as PGC7 or Dppa3) inhibits its binding to the maternal chromatin--a recruitment mechanism analogous to that of Tet3. Although Tet3 and OGT associate with the paternal chromatin independently, both Tet3-dependent 5hmC formation and OGT-mediated H2BS112GlcNAcylation are indispensable for successful ZGA. Together, our findings reveal that a dual epigenetic signature--the simultaneous coordination of DNA hydroxymethylation and histone O-GlcNAcylation by Tet3 and OGT--is essential for initiating transcriptional reprogramming during the maternal-to-zygotic transition.

developmental biology↗

Establishment of a second-generation transgenic marmoset model of polyglutamine disease recapitulating neurological symptoms and pathology

Neurodegenerative diseases, including polyglutamine diseases, remain a major clinical challenge, partly because of limited animal models that recapitulate human disease. Here, we describe a second-generation transgenic marmoset model of spinocerebellar ataxia 3 (SCA3), a polyglutamine disease, which stably expresses expanded CAG repeats in ATXN3. All five offspring of the founder marmoset harbored the transgene with reduced transgene integration sites and without repeat instability or genetic mosaicism, offering improved construct validity. Three of the five marmosets developed progressive motor impairments that segregated into two distinct phenotypes: early onset with rapid progression and late onset with mild progression, accompanied by corresponding patterns in body weight gain and grip strength. Pathological analysis revealed cerebellar Purkinje cell loss, spinal cord neurodegeneration, and widespread intranuclear inclusions. The severity of motor phenotypes correlated with transgene expression levels in disease-relevant brain regions, including the cerebellum, spinal cord, and striatum. By overcoming the common translational limitations of rodent systems, our second-generation model offers a powerful platform for investigating disease mechanisms and testing potential therapeutic interventions. Our results advance the utility of transgenic marmosets as clinically relevant models of neurodegenerative diseases. Summary StatementSecond-generation transgenic marmoset models of spinocerebellar ataxia 3 replicated the progressive motor deficits and neuropathology of the founder marmoset, providing a powerful platform for studying disease mechanisms and developing therapies.

neuroscience↗